279 abstracts found.



Automatic 3D Segmentation of Head and Neck Tumours and Cancerous Lymph Nodes

Year:

Session type:

Theme:

Baixiang Zhao1,John Soraghan1,Gaetano Di-caterina1,Derek Grose2
1university of strathclyde,2Beatson West of Scotland Cancer Centre

PRIMUS 002: An umbrella phase II study examining two neo-adjuvant regimens (FOLFOX-A and AG) in resectable and borderline resectable Pancreatic Ductal AdenoCarcinoma (PDAC)

Year:

Session type:

Theme:

Derek Grose1,Colin McKay2,Nigel Jamieson3,Janet Graham1,David McIntosh1,Fraser Duthie3,Ganesh Radhakrishna4,Dave Colville1,Aileen Dufton1,Peter Houston1,Maria Hawkins5,Rebecca Goody6,Reena Ravikumar7,James Paul8,Jamie Stobo8,Susie Cooke3,Sarah Bradley8,Judith Dixon-Hughes3,Andrew Biankin3,David Chang3
1Beatson West of Scotland Cancer Centre,2West of Scotland Pancreatic Unit, Glasgow Royal,3University of Glasgow,4University of Manchester, Division of Cancer Sciences,5CRUK MRC Oxford Institute for Radiation Oncology,6Leeds Teaching Hospitals NHS Trust,7King’s College Hospital, London,8CRUK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow

Identifying blood bio-markers for immunotherapy toxicity in melanoma patients

Year:

Session type:

Theme:

Anna Olsson-Brown1,Charlotte Hogg1,Marie Allirajah1,Joseph Hanna1,Tsz Hin Lo1,Anusha Yoganathan1,Umair Akbani1,Helen Wong2,Marie McKay3,Shien Chow3,Joseph Sacco2
1University of Liverpool,2University of liverpool,3Clatterbridge Cancer Centre

Investigating the role of NF-κB/RelA in hypoxia induced stemness and EMT characteristics using NF-κB overexpression and CRISPR/Cas9- knockout models of glioblastoma cells.

Year:

Session type:

Theme:

Samna Sagadevan1,Ben Smith1,Vinodh Kannappan1,Sathishkumar Kurusamy1,Karim Azar1,Weiguang Wang1
1University of Wolverhampton

Bioelectical impedance changes during chemotherapy for early breast cancer: The Cando-2 study

Year:

Session type:

Theme:

Stephen Wootton1
1University of Southampton, Southampton, UK

Proteomic Profiling on apoptotic effect of keto-boswellic acid

Year:

Session type:

Theme:

Fahad AL Zadjali1,Asma Bani Oraba1
1Sultan Qaboos University

PARP inhibition causes replication stress in preclinical models of high risk neuroblastoma and synergises with inhibition of ATR

Year:

Session type:

Theme:

Harriet Southgate1,Nicola J Curtin1,Deborah A Tweddle1
1Newcastle University, Newcastle, UK

Patient recruitment for observational and interventional research studies in anal cancer in Leeds, England for 2013-2018

Year:

Session type:

Theme:

Robert Samuel1,David Sebag-Montefiore2,Katie Spenver1,Alex Gilbert1,Nathalie Casanova3,Rachel Cooper3,Louise Loughman3,Pamela Shuttleworth3
1University of Leeds,2Universit of Leeds,3Leed University Teaching Hospitals NHS Foundation Trust

Immune-related hypophysitis: a tertiary referral centre experience

Year:

Session type:

Theme:

Ionut-Gabriel Funingana1,Sarah Welsh1,Benjamin Devoy1,Christine Parkinson1,Krishna Chatterjee1,Pippa Corrie1
1Cambridge University Hospitals NHS Foundation Trust

Development of PLGA-Encapsulated Disulfiram as an orphan drug for MALIGNANT mesothelioma

Year:

Session type:

Theme:

Sathishkumar Kurusamy1,Vinodh Kannappan2,Andrew Pollard3,Garima Tyagi1,Sathishkumar Kurusamy4,Peng Liu5,Yaohe Wang5,Christopher Ireson6,Weiguang Wang7
1University of Wolverhampton,2Disulfican Ltd.,University of Wolverhampton,3Disulfican Ltd., Wolverhampton,4University of wolverhampton,5Barts Cancer Institute,6Pharmidex Ltd, UK,7Disulfican Ltd, University of Wolverhampton

Assessment of CCR5/Maraviroc immunotherapy in combination with PD1 and MR-Guided radiotherapy for treatment of pancreatic cancer

Year:

Session type:

Theme:

Simone Lanfredini1,Sophie Hughes2,Asmita Thapa2,Fiona Bangs2,Jennifer Morton3,Helen Ferry2,Veerle Kersemans2,Paul Kinchesh2,Sean Smart2,Amily Elliot2,James Thompson2,Mark Hill2,Somnath Mukherjee2,Eric O'Neill2
1Oxford University,2University of Oxford,3University of Glasgow

Do Neutrophil Counts Pre-chemotherapy Treatment provide Clinical Value.

Year:

Session type:

Theme:

Pinkie Chambers1,Li Wei2,Yogini Jani3,Ian Wong4
1UCLH NHS Foundation Trust,2UCL School of Pharmacy,3UCL/UCLH Centre for Medicines Optimisation Research and Education,4UCL Research Department of Pharmacy Practice

ADSCaN: A Randomised Phase II study of Accelerated, Dose escalated, Sequential Chemo-radiotherapy in Non-Small Cell Lung Cancer (NSCLC)

Year:

Session type:

Theme:

Claire Lawless1,Kathleen Boyd2,Corinne Faivre-Finn3,John Fenwick4,Tom Haswell5,David Landau6,Jason Lester7,Joe Maguire8,Elaine McCartney1,Jim Paul1,Matthew Hatton9

1CRUK Clinical Trials Unit, Beatson West of Scotland Cancer Centre, Glasgow, UK,2Health Economics & Health Technology Assessment, University of Glasgow, Glasgow, UK,3The Christie NHS Foundation Trust, Manchester, UK,4Gray Institute of Radiation Oncology & Biology, University of Oxford, Oxford, UK,5West of Scotland Cancer Research Consumer Panel, Glasgow, UK,6Guys & St Thomas NHS Trust, London, UK,7Velindre Cancer Centre, Cardiff, UK,8Clatterbridge Cancer Centre, Liverpool, UK,9Weston Park Hospital, Sheffield, UK


The continual reassessment method for phase I clinical trial design: is it always more efficient than the 3+3?

Year:

Session type:

Theme:

Samantha Hinsley1
1Clinical Trials Unit, Cancer Research UK, Glasgow, UK

Neoadjuvant FOLFOXIRI for colorectal cancer – a single-centre retrospective study of outcomes

Year:

Session type:

Theme:

Kimberley Durno1,Daniel Krell1,Hemal Ariyaratne1
1Royal Free London NHS Foundation Trust

Retrospective analysis of the prevalence of family history of psoriasis in patients who develop rheumatological immune-related adverse events (irAEs)

Year:

Session type:

Theme:

Ionut-Gabriel Funingana1,Christine Parkinson1,Sarah Welsh1,Deniz Tafrali2,Pippa Corrie1,Anshuman Malaviya1
1Cambridge University Hospitals NHS Foundation Trust,2Medical University of Graz

Colorectal cancer in patients less than 35 years: 10 year clinical experience from 3 University Hospital Trusts in South East London

Year:

Session type:

Theme:

Julien de Naurois1,Matthaios Kapiris1,Ailsa Sita-Lumsden1,Paul Ross1
1Guy's and St Thomas' NHS Foundation Trust

Flavonoids potentiated anticancer activity of cisplatin in lung cancer by inhibiting histone deacetylases

Year:

Session type:

Theme:

Vivi, Wei Yan1,Christy Wing Sum Tong1,Ming Xia Wu1,Kenneth, Kin Wah To1
1School of Pharmacy, The Chinese University of Hong Kong

PLGA-Disulfiram microparticles inhibit NF-κB and PD-L1 pathway and reverse chemoresistance induced by mesothelioma stem cells.

Year:

Session type:

Theme:

Garima Tyagi1
1Wolverhampton university

CEBOC: Evaluation of the safety of Cediranib in the prevention of Bowel perforation in platinum-resistant Ovarian Cancer

Year:

Session type:

Theme:

Ann White1,Andrew Clamp2,Robert Morgan2,Dilly Goonetilleke3,Angela Casbard4,Tracie-Ann Madden4,Jennifer Swettenham4,Alkesh Patel2,Charlotte Wilhelm-Benartzi4,Catherine Rogers2,Gordon Jayson2
1,2The Christie NHS Foundation Trust,3The University of Manchester,4Cardiff University

Factors associated with Emergency Admissions for Cancer Patients in Last year of life in a UK region

Year:

Session type:

Theme:

Victoria Cairnduff1,Laura Dwyer1,Colin Fox1,Gregory Fallica2,Kelly Shiell-Davis3,Anna Gavin1
1Northern Ireland Cancer Registry, Belfast, UK,2Macmillan Cancer Support,3Macmillan Cancer Support, London, UK

Standardised SACT consent forms improve patient understanding of their treatment intent

Year:

Session type:

Theme:

Iman Ahmed Ainuddin1,Sally Clive2
1University of Edinburgh,2Edinburgh Cancer Centre

EXPERIENCE WITH CDK4/6 INHIBITORS: A SINGLE INSTITUTION STUDY

Year:

Session type:

Theme:

Sarah Saeed Qureshi1,Muhammad Farooq Latif1,Syed Hammad Tirmazy1
1Dubai Hospital

Comparative efficacy of aerobic exercise and pilates exercise on depression, flexibility, functional capacity and quality of life in breast cancer survivors

Year:

Session type:

Theme:

Happiness Aweto1
1University of Lagos

Atezolizumab for locally advanced or metastatic urothelial carcinoma of the urinary tract: Analysis of UK patients treated in the international SAUL study

Year:

Session type:

Theme:

Robert Huddart1,Jason F Lester2,Guy Faust3,Neil McPhail4,Hajer Lassidi5,Simon Fear6,Thomas Powles7
1Institute of Cancer Research,2Velindre Cancer Centre, Cardiff (current affiliation: Swansea Bay University Health Board, Singleton Hospital, Swansea),3Leicester Royal Infirmary NHS Trust, Leicester,4Raigmore Hospital, Inverness,5Roche Products Ltd, Welwyn Garden City,6F Hoffmann-La Roche Ltd, Basel,7Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St Bartholomew’s Hospital, London

Capivasertib plus fulvestrant versus placebo plus fulvestrant in metastatic ER positive breast cancer (FAKTION): A randomised, double-blind, placebo-controlled, phase II trial

Year:

Session type:

Theme:

Robert Jones1,Margherita Carucci2,Angela Casbard2,Rachel Butler3,Catherine Bale4,Fouad Alchami5,Pavel Bezecny6,Johnathan Joffe7,Sarah Moon8,Chris Twelves9,Ramachandran Venkitaraman10,Simon Waters1,Sacha Howell11
1Velindre University NHS Trust, Cardiff, UK,2Cardiff University, Cardiff, UK,3North Bristol NHS Trust, Bristol, UK,4Betsi Cadwaladr University Health Board, Bangor, UK,5Department of Cellular Pathology, University Hospital of Wales, Cardiff, UK,6Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, UK,7Royal College of Physicians of London, London, UK,8University Hospitals of Morecambe Bay NHS Trust, Milnthorpe Cumbria, UK,9University of Leeds and St. James's Institute of Oncology, Leeds, UK,10The Ipswich Hospital NHS Trust, Ipswich, UK,11The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK

Chronic exposure to the novel PARP inhibitor niraparib (ZEJULA®), in contrast to olaparib, limits the impact of chemotherapy-induced multidrug resistance in ovarian cancer

Year:

Session type:

Theme:

Gillian Smith1,Aparajitha Vaidyanathan1,Amber McWhirter1,Lynne Sawers1,Susan Bray1,Kaiming Sun2,Jing Yu Wang2,Michelle Ferguson3
1University of Dundee,2TESARO,3NHS Tayside

Safety and Efficacy of Combined Metronomic Capecitabine with Aromatase Inhibitors for Patients with Newly Diagnosed Metastatic Hormone Positive, HER2 Negative Breast Cancer

Year:

Session type:

Theme:

Badr Abdelmaksoud1,Mostafa Toam2
1faculty of medicine, zagazig university,2zagazig university

A predictive model to estimate the probability of EGFR mutation(s) in New Zealand patients with non-squamous NSCLC

Year:

Session type:

Theme:

Phyu Aye1,Sandar Tin Tin1,Mark McKeage1,Prashannata Khwaounjoo1,Arier Lee1,Alana Cavadino1,Mark Elwood1
1The University of Auckland

Preliminary development of a predictive signature for response to palliative chemotherapy in gastro-oesophageal adenocarcinoma using multilinear singular value decomposition

Year:

Session type:

Theme:

Alan Bilsland1,Eilidh McCulloch2,Jennifer Walker2,Carol McCormick2,Liz-Anne Lewsley3,Antonia McMillan3,Martin MacLeod2,Jamie Stobo3,James Paul3,Patricia Roxburgh2,Sofie Degerman4,Fiona Thomson2,T. R. Jeffry Evans2,W. Nicol Keith2
1Institute of Cancer Science, Wolfson Wohl Cancer Research Centre, University of Glasgow,2Glasgow Experimental Cancer Medicines Centre, Institute of Cancer Science, University of Glasgow,3Cancer Research UK Clinical Trials Unit, Institute of Cancer Science, University of Glasgow,4Department of Medical Biosciences, Umea University

Diethyldithiocarbamate (Imuthiol) reverses hypoxia-induced chemoresistance in multiple myeloma by targeting hypoxia induced NF-kB pathway

Year:

Session type:

Theme:

Gowtham Rajendran1,Vinodh Kanappan1,Basu Supratik2,Weiguang Wang1
1University of Wolverhampton,2The Royal Wolverhampton NHS Trust · Department of Haematology

Can we cure oligometastatic rectal adenocarcinoma with synchronous liver metastasis: a pre-operative short-course radiotherapy and induction chemotherapy regimen.

Year:

Session type:

Theme:

Shagufta Mirza1,Kim Last2,Mark Teo3,Nathalie Casanova3,Rachel Cooper3,David Sebag-Montefiore3,Fei Sun3
1Leeds Teaching Hospital,Leeds, UK,2York Teaching Hospital,York,3Leeds Teaching Hospital, Leeds

Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (MBM; CheckMate 204)

Year:

Session type:

Theme:

Hussein Tawbi1,Peter Forsyth2,F. Stephen Hodi3,Christopher Lao4,Stergios Moschos5,Omid Hamid6,Michael B. Atkins7,Karl Lewis8,Reena P. Thomas9,John A. Glaspy10,Sekwon Jang11,Alain Algazi12,Nikhil I. Khushalani2,Michael A. Postow13,Anna C. Pavlick14,Marc Ernstoff15,David A. Reardon3,Agnes Balogh16,Jasmine Rizzo16,Kim Margolin17
1University of Texas MD Anderson Cancer Center, Houston, US,2Moffitt Cancer Center and Research Institute, Tampa, US,3Dana-Farber Cancer Institute, Boston, US,4University of Michigan, Ann Arbor, US,5University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, US,6The Angeles Clinic and Research Institute, Los Angeles, US,7Georgetown Lombardi Comprehensive Cancer Center, Washington, US,8University of Colorado Comprehensive Cancer Center, Aurora, US,9Stanford University Hospital, Stanford, US,10Jonsson Comprehensive Cancer Center University of California, Los Angeles, US,11Inova Schar Cancer Institute, Falls Church, US, Virginia Commonwealth University, Richmond, US,12University of California–San Francisco, San Francisco, US,13Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, US,14New York University Langone Medical Center, New York, US,15Roswell Park Cancer Institute, Buffalo, US,16Bristol-Myers Squibb, New York, US,17City of Hope, Duarte, US

Palliative radiotherapy to the oesophagus: Less is just as good.

Year:

Session type:

Theme:

Shefali Parikh1,Oliver Coen1,Rebecca Goody1,Ganesh Radhakrishna2,Paul Hatfield1,Mohan Hingorani1
1Leeds Cancer Centre,2The Christie, Manchester

Introducing DPD Screening into Clinical Practice: The Sheffield Experience

Year:

Session type:

Theme:

Alexander Burnett1,Alice Dewdney2
1Weston Park Hospital,2weston park hospital

Using routinely collected population healthcare data, including systemic anti-cancer therapy (SACT) data, to inform commissioning decisions through the Cancer Drugs Fund (CDF)

Year:

Session type:

Theme:

Alice Turnbull1,Sarah Lawton1,Martine Bomb1,Rebecca Smittenaar1
1Public Health England

The rate of neutropenic sepsis in neo-adjuvant FLOT patients and the effect of adding prophylactic GCSF (Granulocyte-Colony Stimulating Factor) to our protocol

Year:

Session type:

Theme:

Apini Patel1
1UCLH

Novel indoline derivatives induce cell death and cell cycle arrest via the deregulation of oncogenic target genes

Year:

Session type:

Theme:

Kumar Subramanian1,Jeyalakshmi Kandhavelu1,Aliyu Musa2,Hande Yapislar3,Meenakshisundaram Kandhavelu2,Paul Ruff1,Clement Penny1
1University of the Witwatersrand,2BioMediTech, Tampere University and Tays Cancer Center,3Acibadem University

Delivery of radiotherapy clinical trials: Recommendations for best practice across Clinical Trial Units (CTU) and the National Radiotherapy Trials Quality Assurance Group (RTTQA)

Year:

Session type:

Theme:

Lisette Nixon1,Elizabeth Miles2,Natalie Abbott3,Sue Bell4,Clare Cruickshank5,Patty Diez6,Alexandra Smith4,Yat Tsang6,Emma Hall5,on behalf of CTRad7
1Cardiff University, Cardiff, UK,2Coordinator National Radiotherapy Trials QA (RTTQA) Group, London, UK, Mount Vernon Cancer Centre, Northwood, UK,3Velindre Cancer Centre, Cardiff, UK,4University of Leeds, Leeds, UK,5The Institute of Cancer Research, London, UK,6Mount Vernon Cancer Centre, Northwood, UK,7National Cancer Research Institute, London, UK

Safety and efficacy of 12 mg/d lenvatinib (LEN) in patients with unresectable hepatocellular carcinoma (uHCC) and bodyweight >80 kg in REFLECT

Year:

Session type:

Theme:

Arndt Vogel1,Masatoshi Kudo2,Ann-Lii Cheng3,Max W. Sung4,Richard S. Finn5,Albert Y. Lin6,Ghassan K. Abou-Alfa7,Angel Alsina8,Valeriy Breder9,Niall Tebbutt10,Pia Osterlund11,C. J. Yen12,Min Ren13,Soamnauth Misir13,Corina E. Dutcus13,Daniel Palmer14,Philippe Merle15,Matthias Pinter16,TR Jeffry Evans17
1Hannover Medical School,2Kindai University School of Medicine,3National Taiwan University Hospital,4Tisch Cancer Institute at Mount Sinai,5Geffen School of Medicine, UCLA Medical Center,6VA Palo Alto Health Care System,7Memorial Sloan Kettering Cancer Center,8Tampa General Hospital,9N.N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation,10Olivia Newton-John Cancer Centre,11Tampere University and Central Hospital,12National Cheng Kung University Hospital,13Eisai Inc.,14University of Liverpool, Liverpool,15CHU de Lyon -Hospital La Croix-Rousse,16Medical University of Vienna,17University of Glasgow

Polyphenols Enhance the Activity of Alkylating Agents in Leukaemia Cell Lines

Year:

Session type:

Theme:

Amani Mahbub1,Dr Nicola Jordan-Mahy2,Prof Christine Le Maitre2,Neil Cross2,Sarah Haywood-Small2
1Umm Al Qura University,2Biomolecular Sciences Research Centre, Sheffield Hallam University

Real-world experience of immune checkpoint inhibitor (ICPI) mediated pneumonitis in patients with metastatic cancer treated at Cambridge University Hospitals NHS Foundation Trust (CUHFT)

Year:

Session type:

Theme:

Orthi Shahzad1,James Jones2,Sarah Welsh2,Jurgen Herre2,Pippa Corrie2
1University of Cambridge,2Cambridge University Hospitals NHS Foundation Trust

Factors influencing the quality of treatment decision-making amongst men diagnosed with localised and locally advanced prostate cancer: findings from a UK-wide mixed methods study

Year:

Session type:

Theme:

Richard Wagland1,Eila Watson2
1University of Southampton,2Oxford Brookes University

TACTICAL: A Phase I/II Trial to Assess the Safety and Efficacy of MSCTRAIL in Metastatic Lung Adenocarcinoma

Year:

Session type:

Theme:

Alice Davies1,Beth Sage2,Krishna Kolluri1,Rebecca Graham1,Ben Weil3,Rita Rego3,Owen Bain3,P. Stephen Patrick4,Kim Champion5,Alex Day5,Bilyana Popova5,Graham Wheeler5,Dan Fullen6,Tammy Kalber4,Martin Forster7,Mark Lowdell3,Sam Janes1
1Lungs for Living, UCL Respiratory, University College London,2Raigmore Hospital, NHS Highlans,3Centre for Cell, Gene and Tissue Therapeutics Royal Free Hospital, NHS Foundation Trust,4Centre for Advanced Biomedical Imaging, University College London,5Cancer Research UK & UCL Cancer Trials Centre, University College London,6Translational Research Office, University College London,7UCL Cancer Institute

Microgel Matrices for Human Cancer Organoid Production

Year:

Session type:

Theme:

Jessica Pinheiro de Lucena-Thomas1,Kim Luetchford2,Marianne Ellis2,Paul De Bank1
1University of Bath,2Cellesce Ltd

TOPARP-B: A Phase II Randomised Trial of the Poly(ADP)-Ribose Polymerase (PARP) Inhibitor Olaparib for Metastatic Castration Resistant Prostate Cancers (mCRPC) with DNA Damage Repair (DDR) Alterations

Year:

Session type:

Theme:

Joaquin Mateo1,Nuria Porta2,Ursula McGovern3,Tony Elliott4,Robert Jones5,Isabel Syndikus6,Christy Ralph7,Suneil Jain8,Mohini Varughese9,Omi Parikh10,Simon Crabb11,Angus Robinson12,Duncan McLaren13,Alison Birtle14,Jacob Tanguay15,Susana Miranda2,George Seed2,Claudia Bertan2,Aude Espinasse2,Peter Chatfield2,Diletta Bianchini16,Emma Hall2,Suzanne Carreira2,Johann De Bono17
1Vall d’Hebron Institute of Oncology, Barcelona, Spain,2The Institute of Cancer Research, London, UK,3University College Hospital, London, UK,4The Christie Hospital, Manchester, UK,5The Beatson West of Scotland Cancer Centre, Glasgow,6The Clatterbridge Cancer Centre, Birkenhead, UK,7St James's University Hospital, Leeds, UK,8Belfast City Hospital, Belfast, UK,9Musgrove Park Hospital, Taunton, UK,10Royal Blackburn Hospital, Blackburn, UK,11Southampton General Hospital, Southampton, UK,12Royal Sussex County Hospital, Brighton, UK,13Western General Hospital, Edinburgh, UK,14Royal Lancaster Infirmary, Lancaster, UK,15Velindre Cancer Centre, Cardiff, UK,16The Royal Marsden NHS Foundation Trust, UK,17The Institute of Cancer Research, London, UK, London & The Royal Marsden NHS Foundation Trust, London, UK

Body composition and chemotherapy toxicity in women with early breast cancer: The Cando-3 study

Year:

Session type:

Theme:

Ramsey Cutress1
1Faculty of Medicine, University of Southampton

Management of Patients with Confirmed Cancer of Unknown Primary: Our Experience

Year:

Session type:

Theme:

Loaie El-Helw1,Sarah Kelt2,Caroline Connolly2,Karthik Kalyanasundaram2,Nicola Lane2,Ola Stankiewicz2,Lorraine Duke2,Tracey Harrison2,Victoria Bateman2,Joanne Harrison2
1Royal Stoke Hospital, UK and Mansoura University, Egypt,2UHNM

New Strategy for the Identification of Squamous Carcinoma Antigens that Induce Therapeutic Immune Responses in Tumor-Bearing Mice

Year:

Session type:

Theme:

Edward Cohen1
1The University of Illinois at Chicago

REACT (REal-time Analytics for Clinical Trials): supporting decision-making for early cancer trials

Year:

Session type:

Theme:

Fouziah Butt1,Dónal Landers1,Paul Fitzpatrick1,Julie Stevenson1,Laura Stephenson1,Richard Hoskins2
1Cancer Research UK, Manchester Institute - digital Experimental Cancer Medicine Team,2The University of Manchester, Research IT